Wellington Management Group
PCVX icon

Wellington Management Group’s Vaxcyte PCVX Stock Holding History

Wellington Management Group’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$326M Sell
5,614,597
-351,713
-6% -$19.1M 0.06% 270
2025
Q4 		$275M Buy
5,966,310
+933,539
+19% +$41.8M 0.05% 316
2025
Q3 		$181M Buy
5,032,771
+77,967
+2% +$2.58M 0.03% 407
2025
Q2 		$161M Sell
4,954,804
-1,462,126
-23% -$47.9M 0.03% 403
2025
Q1 		$242M Buy
6,416,930
+1,972,918
+44% +$158M 0.05% 302
2024
Q4 		$364M Sell
4,444,012
-69,744
-2% -$6.93M 0.07% 241
2024
Q3 		$516M Sell
4,513,756
-79,310
-2% -$7.15M 0.09% 198
2024
Q2 		$347M Sell
4,593,066
-326,304
-7% -$22.2M 0.06% 266
2024
Q1 		$336M Buy
4,919,370
+487,450
+11% +$33.8M 0.06% 298
2023
Q4 		$278M Sell
4,431,920
-166,792
-4% -$8.66M 0.05% 322
2023
Q3 		$234M Buy
4,598,712
+167,501
+4% +$8.26M 0.05% 333
2023
Q2 		$221M Buy
4,431,211
+1,191,937
+37% +$56.5M 0.04% 369
2023
Q1 		$121M Sell
3,239,274
-288,840
-8% -$12.3M 0.02% 498
2022
Q4 		$169M Buy
3,528,114
+1,779,193
+102% +$69.8M 0.03% 421
2022
Q3 		$42M Buy
1,748,921
+1,619,700
+1,253% +$41.1M 0.01% 711
2022
Q2 		$2.81M Sell
129,221
-1,015,594
-89% -$23.5M ﹤0.01% 1473
2022
Q1 		$27.6M Sell
1,144,815
-8,210
-0.7% -$179K ﹤0.01% 939
2021
Q4 		$27.4M Buy
1,153,025
+114,804
+11% +$2.67M ﹤0.01% 1004
2021
Q3 		$26.3M Buy
1,038,221
+160,096
+18% +$3.88M ﹤0.01% 1006
2021
Q2 		$19.8M Sell
878,125
-120,285
-12% -$2.46M ﹤0.01% 1096
2021
Q1 		$19.7M Sell
998,410
-12,440
-1% -$313K ﹤0.01% 1079
2020
Q4 		$26.9M Sell
1,010,850
-87,006
-8% -$3.23M ﹤0.01% 965
2020
Q3 		$54.2M Sell
1,097,856
-102,144
-9% -$4.07M 0.01% 676
2020
Q2 		$37.9M Buy
+1,200,000
New +$38.6M 0.01% 768

Other funds holding PCVX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Wellington Management Group's PCVX Position: Q1 2026 in Review

Wellington Management Group reduced its Vaxcyte (PCVX) stake by 5.9% in Q1 2026, selling an estimated $19.1M and leaving 5,614,597 shares worth $326M. The position accounts for 0.06% of the portfolio, ranked #270.

Wellington Management Group first reported a position in PCVX in Q2 2020 and has held it in 24 quarters since. The position peaked at $516M in Q3 2024. 336 funds tracked by Wall St. Rank hold PCVX as of Q1 2026.

  • Wellington Management Group held 5,614,597 shares of Vaxcyte worth $326M as of Q1 2026.
  • Wellington Management Group sold 351,713 Vaxcyte shares in Q1 2026, an estimated $19.1M.
  • Vaxcyte made up 0.06% of Wellington Management Group's portfolio in Q1 2026, its #270 holding.
  • Wellington Management Group first reported a position in Vaxcyte in Q2 2020 and has held it in 24 quarters since.
  • Wellington Management Group's Vaxcyte position peaked at $516M in Q3 2024.
  • 336 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2026.

Based on Wellington Management Group's 13F filing for Q1 2026, filed 15 May 2026.